FINAL RESULTS ARE AVAILABLE! ¶
By: f.ciompi on July 14, 2022, 11:26 a.m.
Dear TIGER participants,
Once again, thank you for your interest and participation in the TIGER challenge.
Today, we are finally making the final leaderboards public, you can now find them at these links:
We would like to congratulate all participants for their impressive results and for having joined us in this journey, and in particular the following teams for having achieved top-3 positions in at least one of the leaderboard: * Biototem * TIAger * AIVIS * VUNO * SpotlightPathology * 大胖胖墩.
It has been a long way from conceiving the idea of this challenge back in 2019-2020, working with the grand-challenge team on developing the features needed to run evaluations on digital pathology slides on the platform, teaming up with collaborators to collect and annotate the data, and finally kicking-off the challenge in January this year.
TIGER has been the first "type-2" challenge with full whole-slide images as hidden test set on the grand-challenge platform. Because of this, in the past few months our team has been following the developments of this project, seeing how participants were responding to our proposal, and we tried to support all participants with technical support in this fairly new experience for everybody.
We are very happy to see that several teams have worked on this challenge until the very end, and we are glad that we can share the final results with you today by publishing the two final leaderboards.
However, this is not the end of TIGER, actually this is the beginning of a second phase, which consists in several steps.
First, at the end of August, we are planning to organize an online event in the form of a webinar, where we will present all results even in more details, with visual examples, and where we will also ask you to present your solution. In that event, we will also give awards to the winning solutions, as stated in the rules of this challenge.
Second, we are working on several additional experiments to investigate the clinical value of the TILs in breast cancer under multiple aspects. The goal is to include the results of these experiments in a paper describing the results of the challenge and beyond. We envision this phase to be a collaborative project where we can run your solutions on additional datasets. For this purpose, having access to your solutions via grand-challenge and as an open-source code will be key for the success of this project. In parallel with this announcement, we are also reaching out to you via email with some additional details about these latter points.
We will provide additional informations both via this forum and via email in the next few days and weeks, during the Summer period we expect several people to be out of office (including some people from our team), which is why we are planning to organize an event with a ceremony at the end of August/beginning of September.
Regards, The TIGER team